Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6704901 | 0.86 | TSHR (0.57) | NR4A1NR4A2NR4A3TSHRMAPT | |
| SCHEMBL4024078 | 0.86 | TSHR (0.57) | NR4A1NR4A2NR4A3TSHRMAPT | |
| Hydrochloric Acid SCHEMBL6785536 | 0.84 | TSHR (0.55) | NR4A1NR4A2NR4A3TSHRMEN1 | |
| SCHEMBL111301 | 0.84 | CES2 (0.52) | NR4A1NR4A2NR4A3TBXAS1TSHR | |
| Hydrochloric Acid SCHEMBL6786928 | 0.82 | TBXAS1 (0.52) | NR4A1NR4A2NR4A3TBXAS1TSHR | |
| SCHEMBL22397207 | 0.81 | NR4A1 (0.50) | NR4A1NR4A2NR4A3TBXAS1TSHR | |
| SCHEMBL22397208 | 0.81 | NR4A1 (0.50) | NR4A1NR4A2NR4A3TBXAS1TSHR | |
| SCHEMBL24247967 | 0.80 | TSHR (0.44) | TAS1R3TAS1R1TAS1R2MCL1TSHR | |
| SCHEMBL703101 | 0.77 | TSHR (0.65) | TAS1R3TAS1R1TAS1R2MCL1TSHR | |
| SCHEMBL29554593 | 0.77 | MAPT (0.52) | TAS1R3TAS1R1TAS1R2MCL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0910380-B1 | SUBSTITUTED BENZYLIDENE INDENYL FORMAMIDES, ACETAMIDES AND PROPIONAMIDES | CELL PATHWAYS INC (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20020107248-A1 | Method for treating patients with neoplasia by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | OSI PHARMACEUTICALS, INC. | 2002-08-08 | — | — | US | disclosed |
| US-6403831-B1 | 5,6-DIFLUORO-2-METHYL-1-(3,4,5-TRIMETHOXY-BENZYLIDENE)-3-(N-BE NZYL)-INDENYL ACETAMIDE; ANTITUMOR AND ANTICARCINOGENIC AGENT USED TO TREAT PRECANCEROUS LESIONS | CELL PATHWAYS, INC. | 2002-06-11 | — | — | US | disclosed |
| US-6232312-B1 | ADMINISTERING A COMBINATION OF INDENE AND PYRIMIDO(5,4-D)PYRIMIDINE DERIVATIVES TO TREAT PREPANCREATIC CANCER | CELL PATHWAYS, INC. | 2001-05-15 | — | — | US | disclosed |
| EP-0910380-A4 | SUBSTITUTED BENZYLIDENE INDENYL FORMAMIDES, ACETAMIDES AND PROPIONAMIDES | CELL PATHWAYS INC (US) | 2000-09-27 | — | — | EP | disclosed |
| US-6121321-A | IN CARRIER | CELL PATHWAYS, INC. (US) | 2000-09-19 | — | — | US | disclosed |
| US-6063818-A | Substituted benzylidene indenyl formamides, acetamides and propionamides | CELL PATHWAYS INC. (US) | 2000-05-16 | — | — | US | disclosed |
| US-5998477-A | MIXTURE OF DRUG AND CARRIER | CELL PATHWAYS INC. (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0910380-A1 | SUBSTITUTED BENZYLIDENE INDENYL FORMAMIDES, ACETAMIDES AND PROPIONAMIDES | Cell Pathways, Inc. (US) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997047303-A1 | SUBSTITUTED BENZYLIDENE INDENYL FORMAMIDES, ACETAMIDES AND PROPIONAMIDES | CELL PATHWAYS, INC. (US) | 1997-12-18 | — | — | WO | disclosed |
| WO-1997047295-A1 | SUBSTITUTED METHOXY BENZYLIDENE INDENYL-ACETIC AND PROPIONIC ACIDS FOR TREATING PATIENTS WITH PRECANCEROUS LESIONS | CELL PATHWAYS, INC. (US) | 1997-12-18 | — | — | WO | disclosed |
| US-5643959-A | Method for treating patients with precancerous lesions by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | CELL PATHWAYS, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| EP-0508586-B1 | Substituted indenyl compounds | FGN INC (US) | 1995-05-31 | — | — | EP | disclosed |
| US-5401774-A | Treatment of potentially cancerous growths | UNIVERSITY OF ARIZONA (US) | 1995-03-28 | — | — | US | disclosed |
| EP-0508586-A1 | Substituted indenyl compounds | FGN, INC. (US) | 1992-10-14 | — | — | EP | disclosed |
| EP-0485172-A2 | Esters and amides of substituted indenyl acetic acids | FGN, INC. (US) | 1992-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107248-A1 | Method for treating patients with neoplasia by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | VHL, IDH3A, GLI2 | NR4A1 1848/4885NR4A2 1421/4885NR4A3 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.